0.029  -0.003 (-9.52%)		05-08 16:00
Open: 0.034 High: 0.034 Volume: 19,853		Pre. Close: 0.03205 Low: 0.029 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	0.04	1-year :	0.05
Resists	First :	0.03	Second :	0.04
Pivot price	0.03
Supports	First :	0.02	Second :	0.01
MAs	MA(5) :	0.02	MA(20) :	0.03
	MA(100) :	0.04	MA(250) :	3.56
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	56.2	D(3) :	48.1
RSI	RSI(14): 49.3
52-week	High :	26.98	Low :	0.01

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ CERO ] has closed below upper band by 46.1%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 117 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.03 - 0.03	0.03 - 0.03
Low:	0.03 - 0.03	0.03 - 0.03
Close:	0.03 - 0.03	0.03 - 0.03

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.

Mon, 04 May 2026
MSN Money - MSN

Fri, 01 May 2026
[424B3] CERO THERAPEUTICS HOLDINGS, INC. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan

Fri, 01 May 2026
[8-K] CERO THERAPEUTICS HOLDINGS, INC. Reports Material Event - Stock Titan

Fri, 01 May 2026
CERo Therapeutics (CERO) registers 729.6M common shares in S-1 supplement - Stock Titan

Sun, 26 Apr 2026
Cero Therapeutics registers up to 12.5M shares for potential sale under equity agreement with Keystone - MSN

Tue, 21 Apr 2026
CERO Therapeutics (CERO) director files Form 3 ownership - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Biotechnology
Shares Out	37 (M)
Shares Float	35 (M)
Held by Insiders	5 (%)
Held by Institutions	0.1 (%)
Shares Short	193 (K)
Shares Short P.Month	106 (K)

EPS	-22.58
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.61
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-253 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-0.02
Sales Per Share	0
EBITDA (p.s.)	-0.54
Qtrly Earnings Growth	0 %
Operating Cash Flow	-16 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	-0.06
Price to Sales	0
Price to Cash Flow	-0.08

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.